Ricerca announces similarity analysis service
Foresight allows compound assay results to be compared against pharmacologically active compounds
Ricerca Biosciences, a preclinical contract research organisation (CRO) based in Concord, Ohio, US, has launched Foresight, its innovative similarity analysis service.
Foresight allows compound assay results to be compared against the assay results of a large reference set of pharmacologically active compounds.
Ricerca says the tool helps predict in vivo effects from in vitro pharmacology data and provides insight into additional, non-obvious compound activities. It can be used to direct compound modification to avoid adverse effects and determine new indications for safe or novel compounds.
‘Foresight provides a glimpse into the future of a compound and uses data from the past to suggest ways to increase the acuity of that vision,’ said Ian Lennox, chief executive of Ricerca.
‘Additionally, Foresight allows our clients to apply their scientific know-how to years of historical data with sophisticated analysis tools.’
Until 31 August, Ricerca is offering Foresight at an introductory price of US$3,500 per compound.